GLP-1 & Wellness
4 min. read — Last Updated 06/2026
What the data says about the emotional side of GLP-1 weight loss — and why "success" doesn't always feel the way people expect.
A note before you read on: This article is for general information only and isn't medical advice. Always talk to a doctor or other qualified healthcare provider before starting, stopping, microdosing, or changing any medication — including GLP-1 medications like semaglutide or tirzepatide.
Losing weight is supposed to feel good. That's the whole premise — fewer pounds, more confidence, a body that finally matches the goal in your head.
So why do nearly 8 in 10 people using GLP-1 medications say that isn't quite how it played out?
Key Takeaways
- 79% of GLP-1 users agree that losing weight doesn't always equate to feeling better about themselves.
- Cost, not lack of willpower, is the single biggest reason people stop taking GLP-1 medications.
- Most GLP-1 users still rely on exercise and healthy eating alongside their medication — it's a tool, not a replacement.
- Microdosing is gaining attention as a way to reduce side effects and cost, but it remains experimental and should only be discussed with a doctor.
- Most Canadians have never used a GLP-1 medication and aren't planning to — so "everyday" nutrition and habit-building still matter to the vast majority of people managing their weight.
The Gap Between Losing Weight and Feeling Better
Recent consumer research found that 79% of people currently using GLP-1 medications agree that losing weight doesn't always equate to feeling better about themselves. That's a striking number for a treatment built almost entirely around physical results.
Part of the explanation is what these medications actually do. GLP-1s reduce appetite and quiet what's often called "food noise" — the constant background chatter about what to eat next. For many users, that's a genuine relief. But it also changes a person's relationship with food fast, sometimes faster than their relationship with their own body or sense of identity can catch up to.
There's a social layer too. Over two-thirds of GLP-1 users say they feel uncomfortable discussing their weight management with family or friends, and roughly a quarter worry about being judged for their choice — the lingering idea that medication is "cheating" at something willpower is supposed to solve. That stigma is fading as more medical organizations recommend GLP-1s earlier in treatment, rather than as a last resort, but it hasn't disappeared.
The Real Reasons People Stop Taking GLP-1s
If you assume people quit GLP-1 medications because they've hit their goal, the data says otherwise — only about a third of people who stop report doing so because they achieved their health goals.
The bigger drivers:
- Cost. This is consistently the top reason people discontinue. One pharmacy claims review found that even among patients who stuck with treatment, a meaningful share lost insurance coverage within the first year.
- Side effects. Roughly a quarter of users stop because of them.
- Effectiveness concerns. Some users feel the results don't justify the ongoing commitment.
This matters because it reframes GLP-1 use as less of a finish line and more of an ongoing — and often expensive — commitment. For a lot of people, the question isn't "did it work?" but "can I keep affording it?"
Why Microdosing Is Getting Attention
One emerging response to both the cost and side-effect problem is microdosing — taking smaller-than-standard doses of GLP-1 medications. Early research, including a University of Copenhagen study, found that a 1 mg dose of semaglutide produced weight loss results approaching the higher 2.4 mg dose, with fewer reported side effects.
That's promising, but it's also early-stage and unauthorized for general use — there's no established dosing guidance yet, which is exactly why this is a conversation to have with a doctor rather than something to self-manage. Some companies have already launched microdose programs marketed around reduced side effects, which shows real consumer appetite for a "gentler" version of these medications — but appetite for an idea isn't the same as it being medically validated for everyone.
What This Means If You're Managing Weight — With or Without Medication
Here's the part that applies far beyond GLP-1 users: most people, on or off medication, are still trying to build the same basic habits — eating enough protein and fiber, staying satisfied between meals, and not feeling like food is a constant negotiation.
Worth knowing if you're in Canada specifically: the overwhelming majority of Canadians have never used a GLP-1 medication and aren't planning to. So while the conversation around these drugs is loud, most people managing their weight day-to-day are doing it the way they always have — through food, habits, and finding things that actually feel satisfying to eat.
That last point matters more than it sounds. Appetite-suppressing medication or not, research on snacking behavior consistently shows that texture and satisfaction — not just macros — are what keep healthier eating sustainable. A snack that's nutritionally "correct" but joyless tends to get abandoned. One that's both nutrient-dense and genuinely enjoyable to eat is the one people actually stick with.
That's the gap worth paying attention to — not "is this GLP-1 friendly," but "is this something a body managing reduced appetite, reduced budget, or just a busy week can actually look forward to eating."
It's the gap the Allsnack Box was built to close — 237g of protein, 76g of fiber, and under 22g of sugar per box, in snacks designed to satisfy first and check the nutrition boxes second. Discipline never tasted so good.
Sources: Mintel, "Weight Management Trends," consumer research fielded June 2025 (base: 1,639–2,000 internet users aged 18+ currently managing their weight, and 353 current GLP-1 users); Mintel, "Better for You Eating Trends," consumer research fielded March 2026 (Canada). This article reflects findings as of the dates above; medical guidance and product availability may have changed since publication.